Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

In the Phase III IMpower133 trial (NCT02763579), first-line treatment with atezolizumab + carboplatin/etoposide (A+CE) improved OS and PFS vs placebo + carboplatin/etoposide (P+CE) in patients with ES-SCLC. At the time of IMpower133 study closure, patients treated with A+CE were eligible to enrol in the Phase IV, single-arm IMbrella A extension and long-term observational study (NCT03148418). Given the interest in long-term OS data for immunotherapy in ES-SCLC, we report patient outcomes from IMbrella A as an extension of the IMpower133 results.